WO2000037076A1 - Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers - Google Patents
Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers Download PDFInfo
- Publication number
- WO2000037076A1 WO2000037076A1 PCT/FR1999/003207 FR9903207W WO0037076A1 WO 2000037076 A1 WO2000037076 A1 WO 2000037076A1 FR 9903207 W FR9903207 W FR 9903207W WO 0037076 A1 WO0037076 A1 WO 0037076A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- methoxyphenyl
- 9ars
- 3ars
- propenoyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to combinations containing at least one farnesyl transferase inhibitor compound and at least one topoisomerase inhibitor.
- the farnesyl transferase protein is an enzyme which catalyzes the transfer of the farnesyl group of farnesyl pyrophosphate (FPP) to the terminal cysteine residue of the CAAX tetrapeptide sequence of a number of proteins and in particular the p21Ras protein, expressing the oncogene. flush.
- the ras oncogene H-, N- or K-ras is known to play a key role in the pathways of
- the mutation of the ras oncogene or its overexpression is often associated with human cancer: the mutated p21Ras protein is found in many human cancers and in particular in more than 50% of colon cancers and 90% of pancreatic cancers (Kohi et al ., Science, 260, 1834-1837, 1993).
- Topoisomerases are enzymes that control the topology of DNA during replication, transcription and recombination. Two main classes of topoisomerases are known: type I topoisomerases, monomeric enzymes, catalyzing the opening / closing of a single strand of DNA; type II topoisomerases, multimeric enzymes, catalyzing these reactions on both strands of DNA. Type III topoisomerases are also known.
- Topoisomerase inhibitors work by stabilizing the cleavage complex formed by the enzyme attached to the DNA strand. This leads to the production of irreversible DNA cuts, triggering a cellular program of apoptosis.
- camptotecin and its derivatives in particular, topotecan and irinotecan (CPT-11).
- CPT-11 topotecan and irinotecan
- epipodophyllotoxin derivatives such as etoposide and anthracyclines.
- the term “combination” is intended to mean the physical association or the juxtaposition of at least one farnesyl transferase inhibitor compound and of at least one topoisomerase inhibitor in which the compounds may optionally be in separate form.
- combination for the purposes of the invention means combinations which, in addition to at least one farnesyl transferase inhibitor compound and at least one topoisomerase inhibitor, optionally contain one or more substances therapeutically useful in the treatment of diseases neoplastics chosen from: alkylating agents such as cyclophosphamide, ifosfamide, melphalan, rhexamethylmelamine, thiotepa or dacarbazine, antimetabolites such as pyrimidine analogs such as 5-fluorouracil and cytarabine or its analogs such as 2-fluoro deoxycytidine or folic acid analogs such as methotrexate, idatrexate or trimetrexate, spindle poisons including vinca alkaloids such as vinblastine or vincristine or their synthetic analogs such as navelbine, or estramustine or taxoids, epidophyllotoxins such as etoposide or teniposide, antibiotics such as daunor
- the present invention relates to combinations containing at least one farnesyl transferase inhibitor compound and at least one topoisomerase I inhibitor;
- the present invention relates to combinations containing at least one farnesyl transferase inhibitor compound and at least one IL topoisomerase inhibitor.
- a polycyclic aromatic radical such as 1 - or 2-naphthyl or 5-indanyl, or l, 2,3,4-tetrahydronapht-6-yl - a heterocyclic aromatic radical of 5 to 12 members incorporating one or more heteroatoms chosen from oxygen, nitrogen and sulfur atoms, linked to the condensed ring by a carbon-carbon bond, said radical optionally substituted by one or more atoms or radicals, identical or different, chosen from atoms of halogen and the alkyl, alkenyl radicals containing 2 to 4 carbon atoms, hydroxy, alkoxy containing 1 to 4 carbon atoms, mercapto, alkylthio, alkylsulfonyl or alkylsulfinyl, amino, alkylamino or dialkoylamino, formyl, alkylcarbonyl, carboxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl or dialco
- - Xi represents a single bond or an oxygen or sulfur atom
- - m represents an integer equal to 0 or 1
- - n represents an integer equal to 0, 1 or 2
- - one or more methylene radicals may be substituted by a carboxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialcoylcarbamoyl, amino, alkyllamino, dialkoylamino radical with, for all of these radicals, alkyl containing 1 to 4 carbon atoms, - Z represents
- a COOR ⁇ radical in which Ro represents a straight or branched alkyl radical containing 1 to 3 carbon atoms, such as methyl, or
- R 7 represents a hydrogen atom or a straight or branched alkyl radical containing 1 to 6 carbon atoms and
- - a hydroxy radical - an arylsulfonyl radical, such as phenylsulfonyl, optionally substituted by one or more atoms or radicals, identical or different, chosen from halogen atoms and alkyl radicals, alkyloxy, with, for these alkyl radicals containing 1 to 4
- heterocycle incorporating one or more heteroatoms chosen from nitrogen, oxygen or sulfur atoms, said heterocycle possibly being linked by a heteroatom
- aryl such as phenyl, optionally substituted by one or more radicals, identical or different, chosen from alkyl and alkyloxy radicals, for these radicals,
- arylcarbonyl such as benzoyl, optionally substituted by one or more radicals, identical or different, chosen from alkyl radicals, alkyloxy with, for these radicals, alkyl containing 1 to 4 carbon atoms,
- alkyl radical containing 1 to 6 carbon atoms such as methyl, optionally substituted by an amino, alkylamino, dialkoylamino, hydroxy, alkoxy radical containing 1 to 4 carbon atoms, mercapto, alkylthio, alkyloxycarbonyl, carboxy, cyano, a mono- or polycyclic aromatic radical and
- R represents a hydrogen atom or a straight or branched alkyl radical containing 1 to 6 carbon atoms, or
- T represents a hydrogen atom or a straight or branched alkyl radical containing 1 to 6 carbon atoms optionally substituted by an amino, carboxy, alkyloxycarbonyl, hydroxy, alkyloxy, mercapto or alkylthio radical , or
- Ri and R 2 identical or different, represent a hydrogen atom, a halogen atom or an alkyl radical, an alkyloxy radical, such as methoxy, each optionally substituted by a dialkoylamino radical in which each alkyl part contains 1 to 4 carbon atoms or forms with the nitrogen atom a saturated heterocycle containing 5 or 6 members, an alkylthio radical, an alkyloxycarbonyl radical, or alternatively located ortho to one another, Ri and R 2 form a saturated or unsaturated heterocycle containing 1 or 2 heteroatoms chosen from nitrogen and oxygen, optionally substituted by a halogen atom or by an alkyl or alkyloxy radical, preferably one of the symbols Ri or R 2 represents an atom of hydrogen and the other of the symbols represents a methoxy radical, and more advantageously fixed in the ortho position of the phenyl ring, with for all the radicals having an alkyl group, proposed in the defined tion of Ri and R 2 , alkyl containing
- R 3 and R 4 identical or different, represent a hydrogen atom, a halogen atom or an alkyl, hydroxy, alkyloxy, alkylcarbonyloxy, mercapto, alkylthio, alkylsulfonyl or alkylsulfinyl, amino, alkylamino or dialkoylamino, alkyloxycarbonoxyamino alkyloxycarbonyl, carbamoyl alkylcarbamoyl or dialcoylcarbamoyl, formyl, alkylcarbonyl, cyano or trifluoromethyl,
- R 3 and Ri each represent a hydrogen atom, or one of the symbols R or i represents a hydrogen atom and the other of the symbols R or i represents a methoxy radical, and more advantageously in position 5 of the benzoperhydroisoindole nucleus;
- R and R each represent a hydrogen atom; with for all of the radicals having an alkyl group, proposed in the definition of R 3 and R, alkyl containing 1 to 4 carbon atoms.
- R5 represents a hydrogen atom or an alkyl radical, an alkylthio radical, with, for the definition of R 5 , an alkyl containing 1 to 4 carbon atoms;
- R 5 represents a hydrogen atom or a methyl radical
- R 5 represents a hydrogen atom
- - X represents an oxygen or sulfur atom or a group -NH-, -CO-, methylene, alken- 1, 1 -diyl such as vinyldiyl or cycloalkan- 1, 1 -diyl containing 3 to 6 carbon atoms,
- X represents a methylene or vinyldiyl group
- X represents the vinyldiyl group
- Y represents an oxygen or sulfur atom, preferably, Y represents an oxygen atom, in racemic form or their optical isomers, preferably the dextrorotatory enantiomer, as well as the salts of the product of general formula (I).
- famesyl transferase inhibitor compounds the compounds of general formula (I) for which: Ar represents a 2,3-dihydro-1,4-benzodioxin-6-yl or 2 radical , 3- dihydrobenzofuran-5-yl, or a phenyl radical substituted in position 4, preferably by a methyl, trifluoromethyl, methoxy radical,
- R represents a carboxy radical, or a -COOMe radical, or else a -CON (R 7 ) (R 8 ) radical for which when R 7 represents a hydrogen atom, R 8 represents a methyl radical substituted by the radical 3 - pyridyle, one of the symbols Ri or R 2 represents a hydrogen atom and the other of the symbols represents a methoxy radical, and more advantageously fixed in the ortho position of the phenyl ring, or else R and R each represent a hydrogen atom, either one of the symbols R 3 or * represents a hydrogen atom and the other of the symbols R or R 4 represents a methoxy radical, and more advantageously in position 5 of the benzoperhydroisoindole ring,
- R 5 represents a hydrogen atom or a methyl radical
- X represents a methylene or vinyldiyl group
- Y represents an oxygen atom; in racemic form or their optical isomers, preferably the dextrorotatory enantiomer as well as their salts.
- 9SR, 9aRS 4,9-ethano-2 [2- (2-methoxyphenyl) -2-propenoyl] -4-methyl-9- (4-methoxyphenyl) -2,3,3a, 4,9, 9a-hexahydro-1H-benzo [f] isoindole-3a-carboxylic- (3aRS, 4SR, 9SR, 9aRS)
- the present invention relates to combinations containing at least one famesyl transferase inhibitor compound described in application WO 98/2930, incorporated herein by reference, in particular such as those described above, with a topoisomerase I inhibitor;
- a topoisomerase I inhibitor irinotecan (CPT-1) or camptothecin is preferred; more particularly, irinotecan (CPT-11) is cited.
- a composition is active if it makes it possible to limit the growth of the tumor after its administration.
- a particularly advantageous characteristic of the combinations according to the present invention relates to toxicity: in fact, the combinations according to the invention are well tolerated; in combination with the topoisomerase inhibitor, the famesyl transferase inhibitor does not increase the toxicity of the topoisomerase inhibitor; in particular, in combination with irinotecan, product A does not increase the toxicity of irinotecan.
- the combinations according to the present invention have the advantage of prolonging or maintaining the anticancer activity of the topoisomerase inhibitor, in comparison with the activities obtained with each of its constituents considered in isolation; thus, an advantageous characteristic of the combinations according to the invention relates to the increase in the time of tumor growth.
- a combination manifests therapeutic synergism if its therapeutic activity is greater than that of one or other of the constituents used at its optimal dose [THCORBETT et al., Cancer Treatment Reports, 66, 1 187 (1982)]. To demonstrate the effectiveness of a combination, it may be necessary to compare the maximum tolerated dose of the combination with the maximum tolerated dose of each of the constituents isolated in the study under consideration.
- T - C represents the tumor growth delay which is the median time, in days, for the tumors of the treated group (T) and the tumors of the control group (C) to reach a predetermined value (1 g per example) and Tj represents the time, in days, necessary for doubling the tumor volume in control animals [TH CORBETT et al., Cancer, 40, 2660.2680 (1977); F.M.
- An active cytostatic product is a product that helps prevent tumor growth for the duration of treatments. This results in a net log of killed cells having a positive value.
- the combination, used at its own maximum tolerated dose, in which each of the constituents will be present at a dose generally less than or equal to its maximum tolerated dose, will manifest a therapeutic synergy when the net logio of the cells killed will be greater than the value of the net logio killed cells of the best constituent when administered alone.
- the present invention also relates to pharmaceutical compositions containing the combinations according to the invention containing at least one famesyl transferase inhibitor and at least one topoisomerase inhibitor.
- the products which constitute the combination can be administered simultaneously, separately or sequenced over time. This frequency can be adapted so as to obtain the maximum effectiveness of the combination; each administration may have a variable duration ranging from rapid total administration to a continuous infusion.
- the products that make up the combination can be administered at different frequencies. They can be administered independently according to schedules chosen from continuous, intermittent, repeated, alternating or sequential schedules.
- the administrations can be repeated several times a day.
- the famesyl transferase inhibitor having cytostatic activity can be administered according to a continuous schedule; advantageously, this scheme makes it possible to maintain high plasma levels or equal to the concentration required to inhibit 50% of cell growth (IC 5 o) in the in vitro test.
- the topoisomerase inhibitor can be administered according to a schedule depending on the type of tumor model; preferably on an intermittent schedule.
- the combinations are not only limited to those which are obtained by physical association of the constituents, but also to those which allow a separate administration which can be simultaneous or spread over time; in particular, the constituents can be administered independently according to distinct modes, chosen from the oral route, the intraperitoneal route, the parenteral route, the intravenous or topical or rectal route.
- the famesyl transferase inhibitor constituents of the combinations according to the invention can preferably be administered orally; in particular, the famesyl transferase inhibitor constituents of the combinations according to the invention are bioavailable by the oral route.
- the topoisomerase inhibitor constituents of the combinations according to the invention can preferably be administered intravenously or orally in the case of irinotecan.
- Products for intravenous injection are generally sterile pharmaceutically acceptable solutions or suspensions which may optionally be prepared extemporaneously at the time of use.
- nonaqueous solutions or suspensions can be used natural vegetable oils such as olive oil, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate .
- the aqueous sterile solutions can consist of a solution of the product in water.
- the aqueous solutions are suitable for intravenous administration as long as the pH is suitably adjusted and the isotonicity is achieved, for example with a sufficient amount of sodium chloride or glucose. Sterilization can be carried out by heating or by any other means which does not alter the composition.
- the combinations can also be in the form of liposomes or in the form of association with supports such as cyclodextrins or polyethylene glycols.
- compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
- the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
- inert diluents such as starch, cellulose, sucrose, lactose or silica
- These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
- compositions for oral administration there can be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil .
- inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil .
- These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
- compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product (s), excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
- compositions for topical administration can be, for example, creams, lotions, eye drops, mouthwashes, nasal drops or aerosols.
- the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally understood
- famesyle transferase inhibitor between 10 000 mg and 2000 mg per day orally for an adult with unit doses ranging from 50 mg to 1000 mg of active substance.
- topoisomerase inhibitor between 100 mg and 700 mg of active substance per day intravenously for an adult.
- the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
- the treatment can be repeated several times a day or a week until stabilization, partial or total remission or healing.
- the application of the constituents of which may be simultaneous, separate or spread over time, it is particularly advantageous for the amount of the famesyl transferase inhibitor to represent from 10 to 90% by weight of the combination, this content may vary depending on the nature of the associated substance, the desired efficacy and the nature of the cancer to be treated.
- the combinations according to the invention are useful for the treatment of diseases linked to cellular, malignant or benign proliferation, cells of various tissues and / or organs, including muscle, bone or connective tissue, skin, brain, lungs , the sexual organs, the lymphatic or renal systems, the mammary or blood cells, the liver, the digestive system, the colon, the pancreas and the thyroid or adrenal glands, and including the following pathologies: psoriasis, restenosis, various types of sarcomas such as Kaposi's sarcoma, head and neck, pancreas, colon, lung, ovary, breast, brain, prostate, liver, stomach cancer , bladder, kidney, prostate or testis, Wilms tumor teratocarcinomas, cholangiocarcinoma, choriocarcinoma, melanomas, brain tumors such as neuroblastoma, gliomas, multiple myelomas, leukemias and lymphomas such as chronic lymphocytic leukemias, acute
- the combinations according to the invention are particularly useful for the treatment of cancers such as cancers of the pancreas, colon, lung, ovary, breast, brain, prostate, liver, stomach, of the bladder or testes, and more advantageously cancer of the colon and of the pancreas, in particular of the colon.
- cancers such as cancers of the pancreas, colon, lung, ovary, breast, brain, prostate, liver, stomach, of the bladder or testes, and more advantageously cancer of the colon and of the pancreas, in particular of the colon.
- the present invention also relates to the use of combinations containing at least one famesyl transferase inhibitor and at least one topoisomerase inhibitor for the preparation of medicaments useful for the treatment of the abovementioned pathologies; cancers in particular.
- the present invention relates to the use of combinations containing at least one famesyl transferase inhibitor and at least one topoisomerase inhibitor for the preparation of medicaments for simultaneous, separate or sequenced administration over time.
- mice The animals subjected to the experiment, generally mice, are grafted bilaterally by subcutaneous route with 30 to 60 mg of a tumor fragment on day 0.
- the tumors are allowed to grow to the desired size, animals with underdeveloped tumors being eliminated.
- the animals selected are distributed according to their tumor weight homogeneously between the treated and control groups, before the start of the treatments.
- Chemotherapy usually begins 12-14 days after implantation of the tumor and the animals are observed daily.
- the different groups of animals are weighed daily until the maximum weight loss is reached and then the groups are weighed at least once a week until the end of the test.
- Tumors are measured 2 to 3 times a week, using a caliper, according to two measurements in mm which are then converted into tumor weight according to the following formula:
- Tumor weight (mg) Length (mm) x width 2 (mm 2 )
- Tumors are measured two or three times a week until the tumor reaches about 2g or until the animal dies if it occurs before the tumor reaches 2g. The animals are autopsied during the sacrifice.
- the antitumor activity is determined according to the different parameters recorded.
- the animals are grafted with a determined number of cells and the antitumor activity is determined by the increase in the survival time of the treated mice compared to the controls.
- a product is considered to be active if the time to increase survival is greater than 27% and it is considered to be very active if it is greater than 75% in the case of P388 leukemia.
- Size of tumor at the start of treatment 75-260 mg, with a median tumor weight per group of 148-158 mg.
- Size of tumor at the start of treatment 104-208 mg, with a median tumor weight per group of 150 mg.
- the efficacy of the combinations on tumors can also be determined experimentally as follows: The effectiveness of the product A / camptothecin combination is tested sequentially, on cell line;
- a cell line HCT-116 of human colonic carcinoma (supplied by ATCC) are cultivated in a monolayer in a culture medium, Dubelco modified Eagle, containing 2 mM of L-glutamine, 200 U / ml of penicillin, 200 ⁇ g of streptomycin supplemented per 10% by volume of heat-inactivated fetal calf serum.
- the cells in exponential growth are trypsinized, washed with PBS and diluted to a final concentration of 20,000 cells / ml in a complete culture medium.
- the cells are distributed in 25 cm 2 culture flasks (1 ml / vial) and the test compound (camptothecin at final concentrations of 0.001, 0.01, 0.1 ⁇ g / ml) or a volume is added 6 hours after seeding. equivalent of solvent.
- the treated or untreated HCT-116 cells are incubated at 37 ° C. under a CO 2 atmosphere for 24 hours, then the medium is removed, the cells washed with PBS and trypsinized. The number of viable cells is counted by the trypan blue exclusion method and the cells are diluted in complete culture medium to a final concentration of 60,000 cells per ml.
- the cells are seeded on a 96-well microculture plate at the rate of 60,000 cells / ml (0.2 ml / well) in the presence of product A at different concentrations: 3, 1, 0.3, 0.1, 0.03 and 0.01 ⁇ g / ml (in quadruple each) then cultivated for 72 hours. 16 hours before the end of the treatment, neutral red 0.04% is added to each well. At the end of the treatment, the cells are washed and lysed with 1% SDS.
- the incorporation of the dye which reflects cell growth and viability is evaluated by measuring the optical density at 540 nm with a multi-well spectrophotometer. The percentage of growth inhibition is calculated from the optical density obtained for the untreated wells resulting from untreated HCT-116 cells.
- Suspensions of 5 to 80 mg / ml of product A in water containing 0.5% methyl cellulose and 0.5% polysorbate 80 are prepared according to the usual technique for oral administration.
- 5 ml ampoules containing 250 mg of irinotecan diluted for use in water containing 5% glucose are prepared according to the usual technique for intravenous administration.
- compositions are administered separately; preferably, irinotecan is administered twice a day 3 days apart and then, 3 days later, product A is administered, twice a day, for 12 consecutive days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU17838/00A AU1783800A (en) | 1998-12-21 | 1999-12-20 | Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer |
JP2000589187A JP2002532550A (ja) | 1998-12-21 | 1999-12-20 | がん治療のためのファルネシルトランスフェラーゼ阻害剤およびイリノテカンもしくはカンプトテカンの組み合わせ物。 |
EP99961114A EP1140073A1 (fr) | 1998-12-21 | 1999-12-20 | Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine por le traitement de cancers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9816125A FR2787327B1 (fr) | 1998-12-21 | 1998-12-21 | Compositions contenant des inhibiteurs de farnesyle transferase |
FR98/16125 | 1998-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000037076A1 true WO2000037076A1 (fr) | 2000-06-29 |
Family
ID=9534231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/003207 WO2000037076A1 (fr) | 1998-12-21 | 1999-12-20 | Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers |
Country Status (6)
Country | Link |
---|---|
US (1) | US6342487B1 (fr) |
EP (1) | EP1140073A1 (fr) |
JP (1) | JP2002532550A (fr) |
AU (1) | AU1783800A (fr) |
FR (1) | FR2787327B1 (fr) |
WO (1) | WO2000037076A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60016625T2 (de) * | 1999-11-09 | 2005-12-22 | Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) | Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung |
WO2001064194A2 (fr) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Inhibiteur de farnesyl proteine transferase associe a des composes de camptothecine |
US6977247B2 (en) * | 2002-02-21 | 2005-12-20 | Supergen, Inc. | Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
EP1539234A4 (fr) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2 |
AU2003301446C1 (en) | 2002-10-18 | 2010-08-05 | Research Foundation For Mental Hygiene, Inc. | LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis |
US7838531B2 (en) * | 2002-10-18 | 2010-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
EP2316487B1 (fr) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Anticorps IL-9 recombinants et leurs utilisations |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
JP4934426B2 (ja) | 2003-08-18 | 2012-05-16 | メディミューン,エルエルシー | 抗体のヒト化 |
EP2422811A2 (fr) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation d'une spécificité d'anticorps par adaptation sur mesure de son affinité a une antigène apparente |
JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | 抗体のフレームワーク・シャッフル |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
JP5209625B2 (ja) | 2006-08-28 | 2013-06-12 | 協和発酵キリン株式会社 | アンタゴニストのヒトlight特異的ヒトモノクローナル抗体 |
AU2008232902B2 (en) | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
KR101686247B1 (ko) | 2007-10-31 | 2016-12-14 | 메디뮨 엘엘씨 | 단백질 스캐폴드 |
DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
CA2887129A1 (fr) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anticorps anti-c16orf54 et leurs methodes d'utilisation |
SG11201509982UA (fr) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
DK3041507T3 (da) | 2013-08-26 | 2021-07-26 | Biontech Res And Development Inc | Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102614642B1 (ko) | 2014-06-04 | 2023-12-19 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 gd2에 대한 사람 단클론 항체 |
PT3333191T (pt) | 2014-12-11 | 2020-12-15 | Pf Medicament | Anticorpos anti-c10orf54 e suas utilizações |
BR112017015880A2 (pt) | 2015-03-03 | 2018-07-31 | Kymab Ltd | anticorpos, usos e métodos |
EP3909983A1 (fr) | 2015-12-02 | 2021-11-17 | STCube & Co. Inc. | Anticorps et molécules se liant de manière immunospécifique à btn1a1 et leurs utilisations thérapeutiques |
KR20180100122A (ko) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체 |
EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
EP3635007A1 (fr) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1 |
US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
EP3824287A1 (fr) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Récepteur pour vista |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003050A1 (fr) * | 1995-07-10 | 1997-01-30 | Rhone-Poulenc Rorer S.A. | DERIVES DE 4,9-ETHANO-BANZO(f)ISOINDOLE COMME INHIBITEURS DE FARNESYL TRANSFERASE |
WO1998029390A1 (fr) * | 1996-12-30 | 1998-07-09 | Rhone-Poulenc Rorer S.A. | Inhibiteurs de farnesyle transferase |
WO1998054966A1 (fr) * | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Methode de traitement du cancer |
WO1999032114A1 (fr) * | 1997-12-22 | 1999-07-01 | Schering Corporation | Combinaison de composes benzocycloheptapyridines et medicaments antineoplasiques pour le traitement de maladies proliferantes |
WO1999033834A1 (fr) * | 1997-12-23 | 1999-07-08 | Aventis Pharma S.A. | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645988A (en) | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
-
1998
- 1998-12-21 FR FR9816125A patent/FR2787327B1/fr not_active Expired - Lifetime
-
1999
- 1999-07-02 US US09/346,296 patent/US6342487B1/en not_active Expired - Lifetime
- 1999-12-20 AU AU17838/00A patent/AU1783800A/en not_active Abandoned
- 1999-12-20 JP JP2000589187A patent/JP2002532550A/ja active Pending
- 1999-12-20 WO PCT/FR1999/003207 patent/WO2000037076A1/fr not_active Application Discontinuation
- 1999-12-20 EP EP99961114A patent/EP1140073A1/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003050A1 (fr) * | 1995-07-10 | 1997-01-30 | Rhone-Poulenc Rorer S.A. | DERIVES DE 4,9-ETHANO-BANZO(f)ISOINDOLE COMME INHIBITEURS DE FARNESYL TRANSFERASE |
WO1998029390A1 (fr) * | 1996-12-30 | 1998-07-09 | Rhone-Poulenc Rorer S.A. | Inhibiteurs de farnesyle transferase |
WO1998054966A1 (fr) * | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Methode de traitement du cancer |
WO1999032114A1 (fr) * | 1997-12-22 | 1999-07-01 | Schering Corporation | Combinaison de composes benzocycloheptapyridines et medicaments antineoplasiques pour le traitement de maladies proliferantes |
WO1999033834A1 (fr) * | 1997-12-23 | 1999-07-08 | Aventis Pharma S.A. | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
Non-Patent Citations (3)
Title |
---|
MAZET, J.-L. ET AL: "Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells", FEBS LETT. (1999), 460(2), 235-240, XP002135894 * |
VRIGNAUD P. ET AL: "In vivo combination of RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor, with chemotherapy", PROC AM ASSOC CANCER RES, vol. 40, no. 3, March 1999 (1999-03-01), pages 523 - 523, XP002116683 * |
VRIGNAUD, P. ET AL: "RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity", ANN. N. Y. ACAD. SCI. (1999), 886(ANTICANCER MOLECULES), 249-251, XP000905242 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002532550A (ja) | 2002-10-02 |
AU1783800A (en) | 2000-07-12 |
FR2787327B1 (fr) | 2003-01-17 |
EP1140073A1 (fr) | 2001-10-10 |
US6342487B1 (en) | 2002-01-29 |
FR2787327A1 (fr) | 2000-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000037076A1 (fr) | Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers | |
EP0667771B1 (fr) | Compositions antitumorales contenant des derives du taxane | |
CN106536480B (zh) | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
KR20050086715A (ko) | (-)-3-(3,4-디메톡시-페닐)-3-(1-옥소-1,3-디히드로-이소인돌-2-일)-프로피온아미드를 포함하는 조성물 및 그의 사용방법 | |
JP2010510215A (ja) | 有糸分裂進行を阻害するための化合物 | |
KR102452370B1 (ko) | 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법 | |
CA2557540A1 (fr) | Polytherapie contre le cancer comprenant un agent antitumoral et un inhibiteur des hdac | |
KR20170131650A (ko) | 글루타미나제 억제제의 투여 방법 | |
EP1879656A1 (fr) | Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol | |
KR20040004476A (ko) | 3-피리딜 에난티오머 | |
CA2693152C (fr) | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan | |
WO1999058117A1 (fr) | Utilisation de composes reduisant l'apoptose | |
CA2586735C (fr) | Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives | |
EP2655359B1 (fr) | 3-(indolyl)- et 3-(azaindolyl)-4-arylmaléimides conjugués et leur utilisation dans le traitement des tumeurs | |
KR101790193B1 (ko) | 신규한 인돌 유도체 및 이를 포함하는 항암 조성물 | |
KR100377280B1 (ko) | 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물 | |
FR2945747A1 (fr) | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire | |
KR20050075435A (ko) | (+)-3-(3,4-디메톡시-페닐)-3-(1-옥소-1,3-디히드로-이소인돌-2-일)-프로피온아미드의 사용 방법 및 그를포함하는 조성물 | |
FR2937867A1 (fr) | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. | |
JP2005515979A (ja) | 活性な薬物成分としてのビシクロ[3.3.1]ノナン−2,4,9−トリオン置換体 | |
EP3427740B1 (fr) | Nouveau traitement du cancer par une combinaison d'un dérivé phosphorique d'inositol et de chlorure de magnésium | |
JP2006525321A (ja) | 抗癌剤としての併用医薬組成物 | |
FR2778564A1 (fr) | Utilisation de composes reduisant l'apoptose | |
FR2841785A1 (fr) | Utilisation d'au moins deux composes anticancereux, dont un au moins module l'activite du proteasome pour la fabrication d'un medicament destine a traiter le cancer | |
MXPA99005369A (en) | 3-pyridyl enantiomers and their use as analgesics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17838 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 589187 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999961114 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999961114 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999961114 Country of ref document: EP |